Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 17/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20743211 | 0.85 | NLRP3 (0.62) | NLRP3 | |
| SCHEMBL31392652 | 0.73 | NLRP3 (0.65) | NLRP3 | |
| SCHEMBL20757483 | 0.72 | NLRP3 (0.43) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL20743216 | 0.71 | NLRP3 (0.62) | NLRP3 | |
| SCHEMBL31392668 | 0.71 | NLRP3 (0.59) | NLRP3 | |
| SCHEMBL20743272 | 0.71 | CA12 (0.39) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL20743999 | 0.71 | NLRP3 (0.61) | NLRP3 | |
| SCHEMBL23308167 | 0.70 | NLRP3 (0.42) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL20757420 | 0.70 | NLRP3 (0.63) | NLRP3 | |
| SCHEMBL20757385 | 0.69 | NLRP3 (0.62) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-01-03 | — | — | US | disclosed |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, PYCARD | NLRP3 1/4885ATM 3828/4885SMN1; SMN2 3181/4885 |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | NLRP3 1/4885ATM 3828/4885SMN1; SMN2 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.